ALT

Brelyon Named Winner of U.S. Army’s xTechSearch 8 Competition for In-Vehicle Immersive Display

Retrieved on: 
torsdag, maj 30, 2024
Defense, Military, Hardware, Data Management, Wearables, Mobile Technology, Technology, Apps, Applications, Mobile, Wireless, United States Army, ASA, Acquisition, SBIR, ALT, Service, Assistant, Department of Defence, Army, Science, Soldier

Brelyon, a leading innovator in immersive display technologies, has been selected as a winner of the prestigious xTechSearch 8 competition.

Key Points: 
  • Brelyon, a leading innovator in immersive display technologies, has been selected as a winner of the prestigious xTechSearch 8 competition.
  • Alok Mehta, co-founder and COO of Brelyon, expressed his excitement about this significant achievement: "Being named a winner of the xTechSearch 8 competition is a tremendous honor and a testament to Brelyon’s cutting-edge innovation.
  • xTechSearch 8 is the U.S. Army’s only open-topic prize competition, aimed at harnessing new and disruptive technologies from small businesses.
  • For more information about Brelyon and its innovative display technologies, please visit www.brelyon.com .

Shareholders of Altimmune, Inc. Should Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights – ALT

Retrieved on: 
tisdag, maj 28, 2024
NEXT, Defendant, ALT, Fraud, Security (finance)

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
  • Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.

Retrieved on: 
torsdag, maj 23, 2024
Partnership, Hepatology, News, ALT, Viability, Obesity, SAN, Person, Efficacy, Complaint, LLP, Weight loss, Bloomberg, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024.

Key Points: 
  • SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024.
  • The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Intercept Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week® 2024

Retrieved on: 
måndag, maj 20, 2024
Patient, DDW, Primary biliary cholangitis, Hepatology, ALT, Ursodeoxycholic acid, OCA, Liver, Safety, Intercept Pharmaceuticals, Cirrhosis, PBC, Biomarker, Alkaline phosphatase, Gastrointestinal disease, Therapy, ALP, Medical imaging

MORRISTOWN, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, is presenting two new sub-analyses from its Phase 3 POISE study in primary biliary cholangitis (PBC), at Digestive Disease Week® (DDW) 2024 in Washington, D.C. One analysis evaluated the effect of obeticholic acid (OCA) on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, liver biomarkers associated with poor clinical outcomes; the other evaluated the effect of OCA on aminotransferase to platelet ratio index (APRI) score, a non-invasive test that can predict liver fibrosis progression.

Key Points: 
  • “When treating PBC, it’s imperative to assess other biomarkers beyond ALP, such as ALT and AST, as well as potential liver fibrosis, which can be done via non-invasive measures like APRI.
  • Patients were randomized to one of three groups in the trial: placebo, OCA 10 mg, or OCA 5 mg for six months, titrated to 10 mg based on clinical response.
  • The study included a 12-month double-blind phase, as well as a long-term safety extension phase up to five years.
  • A post hoc analysis was conducted to determine the impact of OCA on APRI in patients with PBC from the Phase 3 POISE trial.

Investors who lost money on Altimmune, Inc. (ALT) should contact The Gross Law Firm about pending Class Action - ALT

Retrieved on: 
torsdag, maj 16, 2024
NEXT, Defendant, ALT, Fraud, Security (finance)

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

Key Points: 
  • NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
  • Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action

Retrieved on: 
onsdag, maj 15, 2024
Partnership, Hepatology, News, ALT, Viability, Obesity, SAN, Person, Efficacy, Complaint, LLP, Weight loss, Bloomberg, Pharmaceutical industry

Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.

Key Points: 
  • Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Retrieved on: 
tisdag, maj 14, 2024
Patient, Stomatitis, DL2, Plasma, PD, T-cell prolymphocytic leukemia, Relapse, ALT, Nausea, Tumor microenvironment, CTCL, Therapy, Neoplasm, Arthralgia, Safety, Constipation, Lymphoma, MD, T-PLL, EHA, PTCL, STAT3, Cutaneous T-cell lymphoma, Biomarker, CHL, Fatigue, Infrared spectroscopy correlation table, Peripheral T-cell lymphoma, TPD, European Hematology Association, SOCS3, Annual general meeting

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) --  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new Phase 1 data for KT-333, a first-in-class degrader of STAT3, highlighting safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses will be presented at the European Hematology Association (EHA) Annual Meeting, taking place from June 13-16, 2024, in Madrid, Spain. Results released in an EHA abstract today, which include a data cut-off as of February 6, 2024, demonstrate that KT-333 is a potent and selective STAT3 degrader that has demonstrated clinically significant responses in specific patient populations. The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date.

Key Points: 
  • The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date.
  • “We’re encouraged by the Phase 1 data generated to date.
  • We have also achieved substantial target knockdown and pathway activation,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics.
  • Title: Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

Inipharm to Present Pharmacokinetic Data From a Phase 1 Clinical Trial of INI-822, a Small Molecule Inhibitor of HSD17B13

Retrieved on: 
onsdag, maj 22, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Half-life, Patient, Pharmacokinetics, CDAA, MASH, Plasma, Hepatology, ALT, Liver, Cell membrane, EASL, HSD17B13, Safety, MD, Personal computer, NASH, Rat, Diet, Phospholipid, Alanine transaminase

Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.

Key Points: 
  • Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.
  • The data will be presented at the European Association for the Study of the Liver’s EASL Congress 2024, taking place June 5-8, 2024.
  • In addition, exposures occurred with a half-life that will enable once daily oral dosing in future clinical studies of participants with MASH.
  • These included PCs that have been shown to be elevated in liver biopsies from individuals with the inactive form of the HSD17B13 protein.

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Retrieved on: 
onsdag, maj 22, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, APHP, Hepatology, Clinical research, Viral hepatitis, ALT, AASLD, University, Poster, Safety, Congress, Tariq, Interim, Abstract, Cirrhosis, Liver, Vaccine

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8.
  • This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster , that will highlight the Company’s latest Phase 2 SOLSTICE trial data.
  • The oral presentation will include data on participants who have reached 12 and 24 weeks of chronic suppressive treatment.
  • “Vir remains steadfast in its mission to develop a transformative chronic suppressive therapy for the estimated 12 million or more people living with chronic hepatitis delta.

Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

Retrieved on: 
måndag, maj 20, 2024
Class Action Lawsuit, Professional Services, Legal, Partnership, Hepatology, News, ALT, Viability, Obesity, Person, Efficacy, Complaint, LLP, Weight loss, Bloomberg, Pharmaceutical industry

Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.

Key Points: 
  • Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
  • GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.